Buyback Support Meets Show-Me Phase: Salesforce’s AI Growth Still Needs Proof

What happened

A Seeking Alpha article positions Salesforce as a buy ahead of Q2 earnings, citing modest valuation at 4x revenue and 14x PE, a technical breakout, and a $27.5 billion buyback that reduced shares outstanding by 12%. The DeepValue master report, however, maintains a WAIT rating, emphasizing that the stock is in a 'show me' phase where AI monetization must convert into clean organic growth. The report acknowledges the buyback's per-share support but flags that it was debt-funded, reducing balance-sheet flexibility while the company still needs to prove Agentforce is offsetting seat-pressure risk. Upcoming Q2 results will be critical, with the key metric being current remaining performance obligation (cRPO), which guided to ~14% growth. Overall, the stock has fallen roughly 39% over the past year, and while the article sees limited optimism priced in, the master report argues that waiting for one more quarter of proof is the higher-probability decision.

Implication

The Seeking Alpha article highlights valuation and buyback support, but the master report’s base case implies a fair value of only $170, with a bear case at $145 if cRPO falls below 12% or AI monetization lags. The $27.5 billion debt-funded buyback improves per-share metrics but increases net debt to EBITDA to 0.8x, reducing room for error if growth disappoints. Investors should monitor Q2 cRPO around the guided 14% level and management’s commentary on 2H FY27 organic acceleration before committing capital. A more attractive entry point would be near $150, as per the master report, while trimming above $195 becomes prudent if the stock runs ahead of evidence. Ultimately, the thesis remains unchanged by the article: Salesforce is fundamentally strong but must prove AI-led growth is real and sustainable before the stock can re-rate higher.

Thesis delta

The master report’s WAIT rating and conviction level remain unchanged by the Seeking Alpha article. While the article introduces a more bullish near-term catalyst via buyback and technicals, it does not address the core uncertainty around cRPO and AI monetization that drives the wait-and-see stance. Therefore, no material shift in investment thesis is warranted, though the article signals that some market participants may be pricing in a more optimistic scenario prematurely.